Five-year relative survival for CML in men in England (53%) is similar to the average for Europe (55%). Scotland (65%) and Wales (49%) are also similar to the European average. No five-year survival data is available for Northern Ireland. Across the European countries for which data is available, five-year relative survival in men ranges from 19% (Latvia) to 67% (Sweden).
Five-year relative survival for CML in women in England (47%) is similar to the average for Europe (51%). Wales (57%) and Northern Ireland (53%) are also similar to the European average but Scotland (65%) is above the European average. Across the European countries for which data is available, five-year relative survival in women ranges from 20% (Latvia) to 73% (Sweden).
Chronic Myeloid Leukaemia (C92.1), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007
Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.
Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.
- De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34
About this data
Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, chronic myeloid leukaemia (C92.1)